Thrombin-Assay Substance, fluorescent



Order
Quantity
Price
Status
10 mg 200 € available


Documents
Art. No. D017
Synonym (D)-Phe-Pip-Arg-AMC
Molecular Formula C31H39N7O5
Molecular Weight 589.69
Purity by HPLC >95 % (214 nm)
Appearance Pale yellow solid
Solubility 50 μM in 0.1% (v/v) DMSO / aqueous buffers
Application Highly sensitive fluorogenic thrombin substrate
Lower limit of detection: 5 pM (picomolar) thrombin
Storage Store at -20°C, desiccate
Reference(s) Larsen M.L. et al. Thromb. Res. 1978, 13, 285-288.
Goodnight S.H. Jr. et al. Am. J. Clin. Pathol. 1980, 73, 639-647.
Rijkers D.T. et al. Thromb. Res. 1995, 79, 491-499.
Gram, J. and Jespersen, J. Clinical Chemistry 1995, 31, 1683-1688.
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageSuccessful ISO9001:2015 recertification
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy